Zobrazeno 1 - 10
of 189
pro vyhledávání: '"Edward A. O'Neill"'
Autor:
Seung-Hwan Lee, Ira Gantz, Elizabeth Round, Melanie Latham, Edward A. O’Neill, Paulette Ceesay, Shailaja Suryawanshi, Keith D. Kaufman, Samuel S. Engel, Eseng Lai
Publikováno v:
BMC Endocrine Disorders, Vol 17, Iss 1, Pp 1-9 (2017)
Abstract Background Type 2 diabetes (T2D) is a progressive disease that often requires a patient to use multiple antihyperglycemic agents to achieve glycemic control with disease progression. Omarigliptin is a once-weekly dipeptidyl peptidase-4 inhib
Externí odkaz:
https://doaj.org/article/fd0f014490b14485887e0c37aef648d6
Autor:
Ira Gantz, Menghui Chen, Shailaja Suryawanshi, Catherine Ntabadde, Sukrut Shah, Edward A. O’Neill, Samuel S. Engel, Keith D. Kaufman, Eseng Lai
Publikováno v:
Cardiovascular Diabetology, Vol 16, Iss 1, Pp 1-12 (2017)
Abstract Background Omarigliptin is a once-weekly (q.w.) oral DPP-4 inhibitor that is approved for the treatment of patients with type 2 diabetes mellitus (T2DM) in Japan. To support approval of omarigliptin in the United States, the clinical develop
Externí odkaz:
https://doaj.org/article/e1307a87bfbe4e15adca043c76c5ba45
Autor:
Mollie Ranalletta, Kathleen K. Bierilo, Ying Chen, Denise Milot, Qing Chen, Elaine Tung, Caroline Houde, Nadine H. Elowe, Margarita Garcia-Calvo, Gene Porter, Suzanne Eveland, Betsy Frantz-Wattley, Mike Kavana, George Addona, Peter Sinclair, Carl Sparrow, Edward A. O'Neill, Ken S. Koblan, Ayesha Sitlani, Brian Hubbard, Timothy S. Fisher
Publikováno v:
Journal of Lipid Research, Vol 51, Iss 9, Pp 2739-2752 (2010)
Cholesteryl ester transfer protein (CETP) has been identified as a novel target for increasing HDL cholesterol levels. In this report, we describe the biochemical characterization of anacetrapib, a potent inhibitor of CETP. To better understand the m
Externí odkaz:
https://doaj.org/article/ba8f1fa1fd444c148814f2a249643d10
Autor:
Christopher V McCabe, Peter D Price, Gemma F Codner, Alasdair J Allan, Adam Caulder, Skevoulla Christou, Jorik Loeffler, Matthew Mackenzie, Elke Malzer, Joffrey Mianné, Krystian J Nowicki, Edward J O'Neill, Fran J Pike, Marie Hutchison, Benoit Petit-Demoulière, Michelle E Stewart, Hilary Gates, Sara Wells, Nicholas D Sanderson, Lydia Teboul
Publikováno v:
PLoS Genetics, Vol 20, Iss 3, p e1011187 (2024)
BackgroundRecent developments in CRISPR/Cas9 genome-editing tools have facilitated the introduction of precise alleles, including genetic intervals spanning several kilobases, directly into the embryo. However, the introduction of donor templates, vi
Externí odkaz:
https://doaj.org/article/bb312da1ed8649b9bf1f17a2c3bba609
Autor:
Douglas G. Johns, Louis-Charles Campeau, Puja Banka, An Bautmans, Tjerk Bueters, Elisabetta Bianchi, Danila Branca, Paul G. Bulger, Inne Crevecoeur, Fa-Xiang Ding, Robert M. Garbaccio, Erik D. Guetschow, Yan Guo, Sookhee N. Ha, Jennifer M. Johnston, Hubert Josien, Eunkyung A. Kauh, Kenneth A. Koeplinger, Jeffrey T. Kuethe, Eseng Lai, Christine L. Lanning, Anita Y.H. Lee, Li Li, Anilkumar G. Nair, Edward A. O’Neill, S. Aubrey Stoch, David A. Thaisrivongs, Thomas J. Tucker, Petr Vachal, Kristien van Dyck, Frederic P. Vanhoutte, Bram Volckaert, Dennis G. Wolford, Andy Xu, Tian Zhao, Dan Zhou, Susan Zhou, Xiaohong Zhu, Hratch J. Zokian, Abbas Walji, Harold B. Wood
Publikováno v:
Circulation.
Background: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite
Autor:
Edward N. O'Neill, Milla Neffling, Nick Randall, Grace Kwong, Joshua Ansel, Keith Baar, David E. Block
Publikováno v:
Future Foods. 7:100226
Autor:
Jon Finan, Gary A. Visner, K. Patel, Edward B. O'Neill, Amit Gaggar, Archit Kumar, Nicole M Davis, Hari R. Mallidi, John Dunning, Andreas Seyfang, Grant D. Vestal, Nirmal S. Sharma, Jaskaran Sethi, Muling Lin, Hilary J. Goldberg, Feng Cheng, Mudassir M. Banday, Antonio Coppolino
Publikováno v:
The Journal of Heart and Lung Transplantation. 40:447-457
Background Recent evidence suggests a role for lung microbiome in occurrence of chronic lung allograft dysfunction (CLAD). However, the mechanisms linking the microbiome to CLAD are poorly delineated. We investigated a possible mechanism involved in
Autor:
Asako Sato, Keith D. Kaufman, Yutaka Seino, Masayoshi Shirakawa, Samuel S. Engel, Taro Okamoto, Kohei Kaku, Edward A. O'Neill, Takashi Kadowaki
Publikováno v:
Diabetes, Obesity & Metabolism
Aims To investigate the efficacy, safety and tolerability of sitagliptin 50 mg once daily added to ipragliflozin 50 mg once daily monotherapy in Japanese patients with type 2 diabetes (T2D). Materials and Methods Japanese patients with T2D and glycat
Autor:
Miho Kameya, Tomona Hirano, Yutaka Seino, Nobuyuki Oshima, Samuel S. Engel, Taro Okamoto, Edward A. O'Neill, Ira Gantz, Takashi Kadowaki, Asako Sato, Kohei Kaku
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To evaluate the efficacy and safety of adding the once‐weekly oral dipeptidyl peptidase‐4 inhibitor omarigliptin to treatment of Japanese patients with type 2 diabetes and inadequate glycaemic control on insulin monotherapy. Materials and Met
Autor:
Asako Sato, Keith D. Kaufman, Yutaka Seino, Samuel S. Engel, Kohei Kaku, Taro Okamoto, Edward A. O'Neill, Masayoshi Shirakawa, Takashi Kadowaki
Publikováno v:
Diabetes, Obesity & Metabolism
Aims To assess the efficacy, safety and tolerability of ipragliflozin 50 mg once daily added to sitagliptin 50 mg once daily monotherapy in Japanese patients with type 2 diabetes (T2D). Materials and Methods The results of two clinical trials are rep